AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02932644 — intervention group
Intervention type: OTHER
Intervention: Baseline serum vitamin D level below 50 nmol/l
Description: There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
Study NCT02932644 — intervention group
Intervention type: OTHER
Intervention: Baseline serum vitamin D level at or above 50 nmol/l
Description: There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
Study NCT01878097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Green Dot Bystander Intevention
Description: Intervention allocated at the school level
Study NCT01878097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Awareness Education
Study NCT00889980 — intervention group
Intervention type: OTHER
Intervention: Biospecimen banking
Description: SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
Study NCT02792049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
Study NCT02792049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
Study NCT03926637 — intervention group
Intervention type: OTHER
Intervention: Multiple Sclerosis Performance Test (MSPT)
Description: Administered as specified in the treatment arm.
Study NCT03838380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application
Description: Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
Study NCT00002707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles
Study NCT00002707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles
Study NCT00002707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2 IV every 21 days for 4 cycles
Study NCT00002707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV every 21 days fo 4 cycles
Study NCT00002707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV every 21 days fo 4 cycles
Study NCT00002707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
Study NCT00002707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
Study NCT00754403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
Study NCT04141475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Physiomance acide lipoïque gold
Description: 1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
Study NCT04141475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Physiomance acide lipoïque gold
Description: 1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
Study NCT00790127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1001
Description: HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
Study NCT00790127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered once a day, orally, for 56 days
Study NCT02589028 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: premeal protein-enriched bar intake
Description: Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
Study NCT01195194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRE-TRANSPLANT (PRE=before)
Description: All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL).
Study NCT02015429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasta meal with added fractions or control with no fractions
Study NCT02015429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pasta meal with added fractions or control with no fractions
Study NCT02589028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: breakfast follows by protein bar
Description: Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
Study NCT04302558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Blood Flow Restriction training
Description: While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
Study NCT04302558 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: SHAM Exercise Blood Flow Restriction training
Description: While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
Study NCT00852319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpregnancy Care
Description: The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
Study NCT02881671 — intervention group
Intervention type: GENETIC
Intervention: genetic blood analysis
Description: patients will undergo a blood sample (15 ml) to analyse their genetic profile
Study NCT02823418 — intervention group
Intervention type: PROCEDURE
Intervention: No neuraxial labor analgesia
Description: Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
Study NCT02823418 — intervention group
Intervention type: PROCEDURE
Intervention: Neuraxial labor analgesia
Description: Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
Study NCT01910389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Study NCT01930266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental
Study NCT01930266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Study NCT01764672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Oral dose 40mg (2 x 20mg)
Study NCT02100930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2 3F8 Monoclonal Antibody
Study NCT04006704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF FDC placebo
Description: Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
Study NCT03025152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi
Description: Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
Study NCT03025152 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
Study NCT01444898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
Study NCT02187341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-HTP
Description: Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
Study NCT02187341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
Study NCT02785146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granule is continuously taken three times per day, 20g per time.
Study NCT01764672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral intake of 2 placebo tablets
Study NCT02785146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m², ivdrip, D1
Study NCT01962090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Spine Thrust in Supine Position
Description: The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
Study NCT02262767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Experimental Pfizer compound.
Study NCT02262767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide Hydrochloride
Description: Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Study NCT03772015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
Study NCT02785146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², ivdrip, D1
Study NCT02785146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium folinate
Description: Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
Study NCT01910389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for tadalafil
Study NCT02785146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
Study NCT02785146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 400 mg/m², iv, D1; and 2400mg/m², civ, 48h
Study NCT02785146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400 mg/m², iv, D1; and 2400mg/m², civ, 48h
Study NCT04737980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
Study NCT04737980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hcl 0.5% Inj
Description: Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
Study NCT04737980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
Study NCT04737980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Injection of 8mg (2ml) dexamethasone injectable as admixture
Study NCT00601146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest computed tomography scan
Description: Once a year for three years
Study NCT03521661 — intervention group
Intervention type: PROCEDURE
Intervention: Kyphoplasty
Description: Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
Study NCT02120352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAB Oral Tablets
Description: White to almost white oval shaped film coated 30 mg tablets for oral administration.
Study NCT02120352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
Study NCT02100930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (granulocyte-macrophage colony-stimulating factor)
Study NCT02100930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral isotretinoin
Study NCT03130725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amalgam sealant
Description: Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
Study NCT03130725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin based sealant
Description: Resin based sealant placed on incipient enamel caries and deep enamel fissures.
Study NCT04048889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
Study NCT04048889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
Study NCT04048889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
Study NCT02517086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
Study NCT02517086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: elastic compression
Description: exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
Study NCT00399607 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal biopsy during colonoscopy
Description: Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
Study NCT00399607 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal biopsy at randomization
Description: Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
Study NCT00399607 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal biopsy at 1 year
Description: Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
Study NCT00399607 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal biopsy prior to colonoscopy
Description: Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
Study NCT00399607 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsies during colonoscopy
Description: Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
Study NCT02870062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily baths with chlorhexidine wipes, oral spray and standard shampoo
Description: Description already mentioned in arm/group descriptions.
Study NCT02870062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Daily baths with placebo wipes, oral spray and shampoo
Description: Description already mentioned in arm/group descriptions.
Study NCT03074201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholangioscopy
Description: Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
Study NCT02120352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC Oral tablets
Description: ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
Study NCT02120352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPV Oral Tablets
Description: Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104